Capricor Therapeutics

Capricor Therapeutics, Inc. (Nasdaq:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases. Its lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: CAP-1002, a cardiac cell therapy and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction, advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications.
Type
Public
HQ
Beverly Hills, US
Founded
2005
Size (employees)
29 (est)
Capricor Therapeutics was founded in 2005 and is headquartered in Beverly Hills, US

Capricor Therapeutics Office Locations

Capricor Therapeutics has an office in Beverly Hills
Beverly Hills, US (HQ)
8840 Wilshire Blvd

Capricor Therapeutics Metrics

Capricor Therapeutics Financial Metrics

Revenue (2016)

$4 m

Revenue growth (2015-16), %

(28%)

Net income (2016)

($18.8 m)

Market capitalization (21-Mar-2017)

$67 m

Closing share price (21-Mar-2017)

$3.1

Cash (31-Dec-2016)

$3.2 m
Capricor Therapeutics's current market capitalization is $67 m.
Capricor Therapeutics's revenue was reported to be $4 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$503.2 k$4.8 m$5.5 m$4 m

Revenue growth, %

851%15%(28%)

R&D expense

$5.2 m

General and administrative expense

$2.2 m

Operating expense total

$7.4 m$10.8 m$18.1 m$21 m

EBIT

($6.9 m)($6 m)($12.6 m)($17 m)

EBIT margin, %

(1372%)(126%)(229%)(425%)

Interest expense

$58.1 k$200.5 k$248.6 k$344.7 k

Net Income

($8.9 m)($6.2 m)($12.9 m)($18.8 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$1.7 m$8 m$5.6 m$3.2 m

Accounts Receivable

$187

Inventories

$222.8 k$235.5 k$210.6 k$342.9 k

Current Assets

$3.7 m$11.6 m$14 m$18.1 m

PP&E

$229.5 k$318.6 k$435.3 k

Total Assets

$5.5 m$13.6 m$16.1 m$18.7 m

Accounts Payable

$1.5 m$1.7 m$2.5 m$3 m

Current Liabilities

$2.1 m$6.3 m$6.5 m$4.9 m

Non-Current Liabilities

$4 m$13.6 m$10.6 m$17.9 m

Total Liabilities

$6.1 m$19.9 m$17.1 m$22.8 m

Additional Paid-in Capital

$15.6 m$16.1 m$34.1 m$50 m

Retained Earnings

($22.3 m)($35.2 m)($54 m)

Total Equity

($534.9 k)($6.2 m)($1 m)($4 m)

Financial Leverage

-10.4 x-2.2 x-15.6 x-4.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($8.9 m)($6.2 m)($12.9 m)($18.8 m)

Depreciation and Amortization

$26.9 k$41.9 k$110.9 k$125.7 k

Accounts Receivable

$25 k

Inventories

($161.6 k)($12.6 k)$24.9 k($132.3 k)

Accounts Payable

$974.7 k$70.3 k$831.2 k$508.3 k

Cash From Operating Activities

($6.1 m)$958.6 k($10.8 m)($15.8 m)

Purchases of PP&E

($186.4 k)($129.7 k)($192 k)

Cash From Investing Activities

$3.8 m$141 k($8.1 m)($5.2 m)

Cash From Financing Activities

$3.9 m$5.2 m$16.5 m$18.6 m

Capricor Therapeutics Market Value History

Capricor Therapeutics Online Presence

Capricor Therapeutics Company Life

You may also be interested in